Abstract
The structure of Leishmania major pteridine reductase (PTR1) in complex with NADPH and the inhibitor 2,4,6-triaminoquinazoline (TAQ) has been solved in a new crystal form by molecular replacement and refined to 2.6 Å resolution. The inhibitor mimics a fragment, the pterin head group, of the archetypal antifolate drug methotrexate (MTX) and exploits similar chemical features to bind in the PTR1 active site. Despite being a much smaller molecule, TAQ displays a similar inhibition constant to that of MTX. PTR1 is a target for the development of improved therapies for infections caused by trypanosomatid parasites and this analysis provides information to assist the structure-based development of novel enzyme inhibitors. © 2004 International Union of Crystallography.
Cite
CITATION STYLE
McLuskey, K., Gibellini, F., Carvalho, P., Avery, M. A., & Hunter, W. N. (2004). Inhibition of Leishmania major pteridine reductase by 2,4,6- triaminoquinazoline: Structure of the NADPH ternary complex. Acta Crystallographica Section D: Biological Crystallography, 60(10), 1780–1785. https://doi.org/10.1107/S0907444904018955
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.